Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $13
Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $17 to $13.
Last updated: 2026-11-19 07:32:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Entrada Therapeutics, Inc. (TRDA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5.03, with a market capitalization of $194.19M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.11 to $16.45. This page covers its latest market performance, valuation, price trends and company information.
$194.19M | |
$4.94 | |
$5.51 | |
$4.70 | |
$4.96 | |
744.37K | |
398.84K | |
-- | |
$16.45 | |
$4.11 | |
-- | |
2026-09-30 |
Entrada Therapeutics, Inc. (TRDA) last closed at $5.03 as of 2026-11-19 00:31:00, up 1.41% ($0.07) from the previous close of $4.96.
During the latest regular trading session, TRDA traded between $4.70 and $5.51, with a volume of 744.37K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Entrada Therapeutics, Inc. (TRDA) moved from $5.25 to $5.03, representing a decline of 4.13% ($0.22).
The stock traded between $4.64 and $5.51 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 685.47 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 7.5%
TRDA is currently trading at $5.03, placing it 7.5% of the way from its 52-week low of $4.11 to its 52-week high of $16.45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 152 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Entrada Therapeutics, Inc. and TRDA stock.
Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $17 to $13.
Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing its ELEVATE-45-201 Phase 1/2 clinical study to Cohort 3 at an increased dose of 15 mg/kg for ENTR-601-45, a treatment for Duchenne muscular dystrophy. Cohort 2 enrollment at 10 mg/kg is complete with data expected in H1 2027. The dose escalation allows further evaluation of safety and efficacy profiles, with expectations for higher dystrophin production and functional benefits.
Eligible investors can buy real shares of Entrada Therapeutics, Inc. (TRDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TRDA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TRDA shares and USD.
TRDA Shares to USD
1.00 TRDA shares = 5.033 USD
Calculations are estimates based on the latest available price and are for reference only.